EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention

Tereza Šrámková iD, Tomáš Vaňásek iD, Martin Šrámek iD, Petr Janský iD, Kateřina Benešová iD, Anna Olšerová iD, Silvia Kmetonyová iD, Jaroslava Paulasová-Schwabová iD, Michal Klíma, Lukáš Michal iD, David Kala iD, Jakub Otáhal iD und 2 weitere

Medicine · 2025

DOI: 10.1097/md.0000000000042011 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicine, 2025. Verfasst von Tereza Šrámková und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Anticoagulants, Secondary Prevention, Stroke. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64–76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups ( P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral HemorrhageAnticoagulantsSecondary PreventionStrokeHumansMaleFemaleAgedMiddle AgedMagnetic Resonance ImagingDabigatranIncidencePyridonesPyrazoles

Stichwörter der Autor:innen

anticoagulationmicrobleedsstroke

Substanzen

AnticoagulantsapixabanDabigatranPyridonesPyrazoles

Autor:innen und Institutionen

  • Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic.
  • Department of Radiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic.
  • Department of Neurology, Military University Hospital Prague, Czech Republic.
  • Department of Neurology, Jihlava Hospital, Czech Republic.
  • Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic.

ORCID-Profile: Tereza Šrámková, Tomáš Vaňásek, Martin Šrámek, Petr Janský, Kateřina Benešová, Anna Olšerová, Silvia Kmetonyová, Jaroslava Paulasová-Schwabová, Lukáš Michal, David Kala, Jakub Otáhal

Zitieren

APA

Šrámková, T., Vaňásek, T., Šrámek, M., Janský, P., Benešová, K., Olšerová, A., Kmetonyová, S., Paulasová-Schwabová, J., Klíma, M., Michal, L., Kala, D., Otáhal, J., Mikšík, L., & Tomek, A. (2025). Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention. Medicine. https://doi.org/10.1097/md.0000000000042011

Vancouver

Šrámková T, Vaňásek T, Šrámek M, Janský P, Benešová K, Olšerová A, et al. Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention. Medicine. 2025. doi:10.1097/md.0000000000042011

BibTeX
@article{rmkov2025,
  author = {Šrámková, Tereza and Vaňásek, Tomáš and Šrámek, Martin and Janský, Petr and Benešová, Kateřina and Olšerová, Anna and Kmetonyová, Silvia and Paulasová-Schwabová, Jaroslava and Klíma, Michal and Michal, Lukáš and Kala, David and Otáhal, Jakub and Mikšík, Lukáš and Tomek, Aleš},
  title = {Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention},
  journal = {Medicine},
  year = {2025},
  doi = {10.1097/md.0000000000042011}
}
Kostenlos starten →